An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO: 1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO: 1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S
An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO: 1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO: 1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO: 13). The immunogens can be used in compositions and in the treatment of disorders.
대표청구항▼
1. A composition comprising a dendritic cell that presents on its surface a human leukocyte antigen (HLA) A2 immunogen of 9 to 20 amino acid residues in length comprising a peptide consisting of the amino sequence of SEQ ID NO: 1 (ILSAFSVYV) with four or fewer amino acid substitutions within SEQ ID
1. A composition comprising a dendritic cell that presents on its surface a human leukocyte antigen (HLA) A2 immunogen of 9 to 20 amino acid residues in length comprising a peptide consisting of the amino sequence of SEQ ID NO: 1 (ILSAFSVYV) with four or fewer amino acid substitutions within SEQ ID NO: 1, wherein there are no amino acid substitutions at position 2 or position 8 of SEQ ID NO: 1, wherein the peptide is a CD133 HLA-A2 restricted epitope, and wherein administration of the composition elicits a peptide-specific cytotoxic T lymphocyte response against HLA-A2 expressing cells that present the CD133 epitope. 2. The composition of claim 1, wherein the dendritic cell acquired the peptide epitope in vitro by exposure to a synthetic peptide from CD133 that is 9 to 30 amino acids in length. 3. The composition of claim 1, wherein the composition further comprises a pharmaceutically-acceptable carrier, diluent, or excipient. 4. The composition of claim 1, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one or two amino acid substitutions within SEQ ID NO: 1. 5. The composition of claim 1, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one amino acid substitution within SEQ ID NO: 1. 6. The composition of claim 1, wherein the immunogen comprises a peptide consisting of 9 to 15 amino acids. 7. The composition of claim 6, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one or two amino acid substitutions within SEQ ID NO: 1. 8. The composition of claim 6, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one amino acid substitution within SEQ ID NO: 1. 9. The composition of claim 1, wherein the immunogen comprises a peptide consisting of 9 to 12 amino acids. 10. The composition of claim 9, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one or two amino acid substitutions within SEQ ID NO: 1. 11. The composition of claim 9, wherein the immunogen comprises a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one amino acid substitution within SEQ ID NO: 1. 12. The composition of claim 1, wherein the composition further comprises one or more of an adjuvant, a cytokine, a vehicle, a liposome, an immuno-stimulating complex (ISCOM), or a slow-releasing particle. 13. The composition of claim 12, comprising an adjuvant. 14. The composition of claim 13, wherein the adjuvant is selected from the group consisting of Toll-like receptor agonists, Bacillus Calmette Guerin, complete or incomplete Freund's adjuvant, a cytosine guanine oligodeoxynucleotide, Montanide ISA-51, Activation Gene-3, aluminum phosphate, aluminum hydroxide, alum, and saponin. 15. The composition of claim 12, comprising a cytokine. 16. The composition of claim 15, wherein the cytokine is selected from the group consisting of Interleukin-1, Interleukin-2, Interleukin-7, Interleukin-12, Interleukin-13, Interleukin-15, tumor necrosis factor, stem cell factor, and granulocyte monocyte colony stimulating factor. 17. The composition of claim 1, wherein the immunogen is linked to an immunogenic carrier. 18. The composition of claim 17, wherein the immunogenic carrier is selected from the group consisting of a serum albumin, tetanus toxoid, keyhole limpet hemocyanin, dextran, an agonist of a Toll-like receptor, and a recombinant virus particle.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (48)
Rosenberg Steven A. (Bethesda MD), Adoptive immunotherapy as a treatment modality in humans.
Graus, Yvo Maria Franciscus; Smit, Hobbe Friso; Osterhaus, Albertus Dominicus Marcellinus Erasmus; Hageman, Robert Johan Joseph, Chlorogenic acid and an analog thereof for immune system stimulation.
Altman John D. (San Carlos CA) McHeyzer-Williams Michael G. (Menlo Park CA) Davis Mark M. (Atherton CA), Compositions and methods for the detection, quantitation and purification of antigen-specific T cells.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
Hideaki Tahara JP; Michael T. Lotze ; Yasuhiko Nishioka JP, In situ injection of antigen-presenting cells with genetically enhanced cytokine expression.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Cohen Peter A. ; Czerniecki Brian J. ; Koski Gary K. ; Weng David E. ; Carter Charles ; Ojeifo John O. ; Schwartz Gretchen N., Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells.
Cohen Peter A. (Bethesda MD) Czerniecki Brian J. (Gaithersburg MD) Carter Charles (Gaithersburg MD) Fowler Daniel H. (Bethesda MD) Kim Hyun (Rochester MN), Method for isolating dendritic cells.
Edward L. Nelson ; Susan L Strobl, Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells.
Storkus Walter J. ; Lotze Michael T., Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients.
Boon Thierry,BEX ; Van Der Bruggen Pierre,BEX ; Van Den Eynde Benoit,BEX ; Van Pel Aline,BEX ; De Plaen Etienne,BEX ; Lurquin Christophe,BEX ; Chomez Patrick,BEX ; Traversari Catia,ITX, Tumor rejection antigen precursors, tumor rejection antigens and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.